{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053527","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.912249+00:00","generated_at":"2026-06-02T22:26:38.047883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive","bullets":["Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).","Net loss $14.8M for Q1 2024 vs $16.8M same quarter 2023; includes $3.9M stock-based comp.","R&D expense $7.6M (down $2.1M YoY) on lower compensation and third-party costs.","RT-111 (oral anti-IL-12/23 antibody) Phase 1 achieved high bioavailability, well-tolerated, no serious AEs.","Expects Phase 2 trial for RT-102 (osteoporosis) in 2024; RaniPill HC Phase 1 readiness H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053527","json":"https://secwatch.observer/filing/0000950170-24-053527.json","markdown":"https://secwatch.observer/filing/0000950170-24-053527.md","text":"https://secwatch.observer/filing/0000950170-24-053527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/0000950170-24-053527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/rani-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:26:38.047883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea7a11aa2c44fb2dd245913bc51103f682d9d59b","claim":"Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $14.8 million.","evidence_excerpt":"Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/0000950170-24-053527-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2024 was $14.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}